Form D · Biotechnology
AnBio Therapeutics Ltd.
New York, NY · CIK 0001887703
Offering snapshot reported Oct 13, 2021 · SEC filing
- Reported sold
- $60.9M Offering amount: $60.9M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $200K Reported outside-investor minimum
- First sale
- Sep 24, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 13, 2021 | Initial | $60,850,000 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $1.84M
- Form D file number
- 021-416641
Source: Form D, filed Oct 13, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ting Jia | Director |
| Xiaohang (Tony) Tong | Director |
| Junyuan Wang | Director, Executive |
| Wei Xu | Director |
| Bing Yan | Director, Executive |
| Lihua Zheng | Director, Executive |
| Zhengwei Zhu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
777 Third Avenue, Suite 1704
New York, NY, 10017
New York, NY, 10017